- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04446819
Compression Gloves to Reduce Albumin-binding Paclitaxel Induced Peripheral Sensory and Motor Neurotoxicity (REMAINING) (REMAINING)
July 24, 2020 updated by: Jian Zhang,MD, Fudan University
A Multicenter Prospective Phase III Clinical Study of Reducing Albumin-binding Paclitaxel Induced Peripheral Sensory and Motor Neurotoxicity of Upper Extremities With Compression Gloves (REMAINING)
Nanoparticle albumin-bound paclitaxel has greater efficacy and favorable safety profile than standard paclitaxel.
However, rate of neuropathy caused by nanoparticle albumin-bound paclitaxel is higher than standard paclitaxel, and is one of its dose-limited toxicities.
Previously, compression therapy by surgical gloves has shown effectiveness in preventing chemotherapy-induced neuropathy.
We designed this multi-center prospective self-control phase III study to investigate the efficacy of compression gloves to reduce albumin-binding paclitaxel induced sensory and motor neurotoxicity of upper extremities.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
70
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jian Zhang, PhD
- Phone Number: 86-21-64175590
- Email: syner2000@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Fudan University Shanghai Cancer Center
-
Contact:
- Jian Zhang, PhD
- Phone Number: 86-21-64175590
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients are diagnosed with pathologically confirmed solid tumors.
- Patients are about to receive albumin-binding paclitaxel monotherapy (at least 4 cycles anticipated) by physicians' choice.
- Patients should have baseline Grade 0 peripheral sensory and motor neurotoxicity (NCI-CTCAE 5.0).
- Eastern Cooperative Oncology Group performance status ≤ 1.
Biochemical tests within 7 days before inclusion should meet the following criteria:
- Hemoglobin ≥ 90g/L, white blood cell count ≥ 3500/mm^3, neutrophil ≥ 1500/mm^3 and platelet ≥ 75000/mm^3 with no blood transfusion or hematopoietic colony-stimulating factors in the past 14 days.
- Creatinine ≤ 1.5 times upper limit of normal (ULN).
- Liver function: For patients without liver metastasis, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) ≤ 1.5 times ULN, and total bilirubin ≤ 1.25 times ULN. For patients with liver metastasis, ALT, AST and ALP ≤ 5 times ULN and total bilirubin ≤ 1.5 times ULN.
- Life expectancy ≥ 12 weeks.
- No history of severe diseases in important organs including heart, lung, liver, and kidney.
- Willingness to sign a written informed consent.
- Willingness to adhere to dose and visit schedules.
- Women of child-bearing ages should be willing to take birth control methods during treatment and within 8 weeks after trial, and pregnancy test (blood or urine) within 14 days before inclusion should be negative (if positive, ultrasound should be performed to rule out pregnancy). Male patients should be willing to take birth control methods during treatment and within 8 weeks after trial or be sterilized by surgery .
Exclusion Criteria:
- Patients with uncontrolled and severe infection.
- Patients with meningeal metastasis, symptomatic brain metastasis, spinal cord compression, or new discovery of brain or pia mater diseases during screening. Patients who finish brain local control treatment, manifest stable symptoms and without brain hemorrhage in radiological screening can be included in the trial.
- Investigators decide the patient unsuitable for the trial.
Elimination Criteria:
- Patients have allergy to albumin-binding paclitaxel and are unable to finish 4 cycles of treatment.
- Patients are unable to finish 4 cycles of albumin-binding paclitaxel monotherapy due to intolerable toxicities even after twice dose reduction. If due to toxicity of peripheral neurotoxicity, evaluations should be performed and recorded for further case study.
- Patients are unable to finish 4 cycles of albumin-binding paclitaxel monotherapy because of change of regimen due to progression or death.
- Patients require to quit.
- Patients are found to have situations that are not suitable for the trial after inclusion.
- Patients' hands are unfit for the compression gloves used in the trial (too big or too small).
- Any situations that investigators believe necessary for patients to quit the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Cohort
Patients diagnosed with solid tumors who are about to received albumin-binding paclitaxel monotherapy are recruited.
Dominant hands and non-dominant hands are treated with small-size compression gloves and suitable-size compression gloves, respectively, during the administration of albumin-binding paclitaxel.
|
Patients wear small-size compression gloves (one or two size smaller than suitable size) for dominant hands and suitable-size compression gloves for non-dominant hands for 90 minutes during the administration of albumin-binding paclitaxel (start from 30 minutes before albumin-binding paclitaxel infusion).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Differences in severe peripheral sensory neurotoxicity rates
Time Frame: 3 weeks after Cycle 4 administration and/or 1 day before Cycle 5 administration of albumin-binding paclitaxel (each cycle is 21 days).
|
Differences in peripheral sensory neurotoxicity (NCI-CTCAE Grade 2-5) rates between dominant hands and non-dominant hands after 4 cycles of albumin-binding paclitaxel monotherapy.
|
3 weeks after Cycle 4 administration and/or 1 day before Cycle 5 administration of albumin-binding paclitaxel (each cycle is 21 days).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Differences in total peripheral sensory neurotoxicity rates
Time Frame: 3 weeks after Cycle 4 administration and/or 1 day before Cycle 5 administration of albumin-binding paclitaxel (each cycle is 21 days).
|
Differences in total peripheral sensory neurotoxicity (NCI-CTCAE Grade 1-5) rates between dominant hands and non-dominant hands after 4 cycles of albumin-binding paclitaxel monotherapy.
|
3 weeks after Cycle 4 administration and/or 1 day before Cycle 5 administration of albumin-binding paclitaxel (each cycle is 21 days).
|
Differences in severe peripheral motor neurotoxicity rates
Time Frame: 3 weeks after Cycle 4 administration and/or 1 day before Cycle 5 administration of albumin-binding paclitaxel (each cycle is 21 days).
|
Differences in severe peripheral motor neurotoxicity (NCI-CTCAE Grade 2-5) rates between dominant hands and non-dominant hands after 4 cycles of albumin-binding paclitaxel monotherapy.
|
3 weeks after Cycle 4 administration and/or 1 day before Cycle 5 administration of albumin-binding paclitaxel (each cycle is 21 days).
|
Differences in total peripheral motor neurotoxicity rates
Time Frame: 3 weeks after Cycle 4 administration and/or 1 day before Cycle 5 administration of albumin-binding paclitaxel (each cycle is 21 days).
|
Differences in total peripheral motor neurotoxicity (NCI-CTCAE Grade 1-5) rates between dominant hands and non-dominant hands after 4 cycles of albumin-binding paclitaxel monotherapy.
|
3 weeks after Cycle 4 administration and/or 1 day before Cycle 5 administration of albumin-binding paclitaxel (each cycle is 21 days).
|
Differences in peripheral neurotoxicity questionaire scores
Time Frame: 3 weeks after Cycle 4 administration and/or 1 day before Cycle 5 administration of albumin-binding paclitaxel (each cycle is 21 days).
|
Differences in peripheral neurotoxicity questionaire scores between dominant hands and non-dominant hands after 4 cycles of albumin-binding paclitaxel monotherapy.
|
3 weeks after Cycle 4 administration and/or 1 day before Cycle 5 administration of albumin-binding paclitaxel (each cycle is 21 days).
|
Safety of compression gloves in preventing albumin-binding paclitaxel induced neurotoxicity.
Time Frame: From date of consent to one months after Cycle 4 administration of albumin-binding paclitaxel (each cycle is 21 days).
|
Adverse events related to compression gloves intervention are collected.
|
From date of consent to one months after Cycle 4 administration of albumin-binding paclitaxel (each cycle is 21 days).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jian Zhang, PhD, Department of Medical Oncology, Fudan University Shanghai Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 12, 2020
Primary Completion (Anticipated)
January 1, 2022
Study Completion (Anticipated)
June 1, 2022
Study Registration Dates
First Submitted
June 18, 2020
First Submitted That Met QC Criteria
June 22, 2020
First Posted (Actual)
June 25, 2020
Study Record Updates
Last Update Posted (Actual)
July 28, 2020
Last Update Submitted That Met QC Criteria
July 24, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BUAY-20-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Neuropathy
-
Arash Asher, MDVoxxLifeRecruitingNeuropathy | Chemotherapy-induced Peripheral Neuropathy | Neuropathy;PeripheralUnited States
-
Beth Israel Deaconess Medical CenterPhoenix Neurological Associates, LTDCompletedSmall Fiber Neuropathy | Idiopathic Peripheral NeuropathyUnited States
-
M.D. Anderson Cancer CenterFoundation for Anesthesia Education and ResearchRecruitingNeuropathy;PeripheralUnited States
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Yale University; University of Manchester; Maastricht University; Ospedale San... and other collaboratorsUnknownPainful Peripheral Neuropathy | Painless Peripheral Neuropathy
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UnknownDiabetic Peripheral Neuropathy
-
Hawler Medical UniversityUnknownDiabetic Peripheral NeuropathyIraq
-
Baylor College of MedicineNeuroMetrix, Inc.RecruitingPain | Neuropathy | Chemotherapy-induced Peripheral NeuropathyUnited States
-
Institut Cancerologie de l'OuestGrünenthal GmbHNot yet recruitingChemotherapy-induced Peripheral Neuropathy
-
Odense University HospitalAarhus University Hospital; University of Southern Denmark; Sygehus LillebaeltRecruitingChemotherapy-induced Peripheral NeuropathyDenmark
Clinical Trials on Compression gloves
-
Hôpital Léon BérardTerminated
-
Clalit Health ServicesUniversity of HaifaCompletedColles' Fracture | Distal Radius Fractures | Fracture of Lower End of Radius | Smith's FractureIsrael
-
Young-Joon KangRecruitingChemotherapy-induced Peripheral NeuropathyKorea, Republic of
-
Celal Bayar UniversityCompletedOrthopedic Disorder | Puncture | Surgical GlovesTurkey
-
Medical University InnsbruckCompletedHealth Education | Hygiene | Equipment ContaminationAustria
-
University of VirginiaCompletedNeonatal Infection | Neonatal Necrotizing EnterocolitisUnited States
-
Centre Leon BerardActive, not recruitingBreast Cancer | Colorectal CancerFrance
-
khalid abd aziz mohamedArmed Forces Hospitals, Southern Region, Saudi ArabiaUnknownDecreasing Wound InfectionSaudi Arabia
-
Hugo W. Moser Research Institute at Kennedy Krieger...Johns Hopkins UniversityTerminated
-
Mereo BioPharmaCompleted